scholarly journals Clinical Efficacy of a West African Sorghum bicolor-Based Traditional Herbal Preparation Jobelyn Shows Increased Hemoglobin and CD4+ T-Lymphocyte Counts in HIV-Positive Patients

2014 ◽  
Vol 20 (1) ◽  
pp. 53-56 ◽  
Author(s):  
Godwin I. Ayuba ◽  
Gitte S. Jensen ◽  
Kathleen F. Benson ◽  
Ademola M. Okubena ◽  
Olajuwon Okubena
Keyword(s):  
Sorghum Bicolor ◽  
Clinical Efficacy ◽  
T Lymphocyte ◽  
West African ◽  
Hiv Positive ◽  
Herbal Preparation

Notes on the biology and immature stages of West African sorghum head bugs Eurystylus immaculatus and Creontiades pallidus (Heteroptera: Miridae)

1994 ◽  
Vol 84 (3) ◽  
pp. 383-388 ◽  
Author(s):  
A. Ratnadass ◽  
B. Cissé ◽  
K. Mallé
Keyword(s):  
Sorghum Bicolor ◽  
Incubation Period ◽  
West African ◽  
Immature Stages ◽  
Egg Incubation ◽  
Eurystylus Immaculatus ◽  
Creontiades Pallidus

AbstractDetailed studies on the immature stages of the sorghum head bugs, Eurystylus immaculatus Odhiambo and Creontiades pallidus Rambur, were carried out in the laboratory at Samanko, Mali, during November 1991 to March 1992, and January to April 1993, and in the field in October 1993. Eggs of both species were laid in maturing sorghum (Sorghum bicolor) grains. The egg incubation period was 4–7 days in E. immaculatus, and 5–7 days in C. pallidus. There were five nymphal instars in both species. The total nymphal period was 6–11 days in E. immaculatus and 8–14 days in C. pallidus. The durations of first, second, third, fourth and fifth nymphal instars were 1–3, 1–2, 1–2, 1–3 and 1–3 days, respectively, in E. immaculatus, and 1–3, 1–2, 1–3, 2–3 and 2–4 days, respectively, in C. pallidus. All the immature stages of E. immaculatus are described and sketched.

scholarly journals The West African Sorghum Bicolor Leaf Sheath Extract Jobelyn® and Its Diverse Therapeutic Potentials

2017 ◽  
Author(s):  
Samira Makanjuola ◽  
Olajuwon Okubena ◽  
Louis Ajonuma ◽  
Adedoyin Dosunmu ◽  
Solomon Umukoro ◽  
...  
Keyword(s):  
Sorghum Bicolor ◽  
Leaf Sheath ◽  
West African ◽  
Biologically Active ◽  
In Vivo Studies ◽  
The West ◽  
Total Extract ◽  
Active Compounds

The West-African variety of Sorghum bicolor leaf sheath (SBLS) Jobelyn® is a natural remedy, which has gained international recognition for its anti-anemic effect and energy boosting qualities in debilitating diseases. The widespread use of traditional medicine in the region usually confirms its safety, but not its efficacy or deep assessment of their pharmacological properties. The other major issue for herbal-based treatments is the lack of definite and complete information about the composition of the extracts.  Despite limitations, efforts have been made in isolation and characterisation of active compounds in this specie of sorghum showing various subclasses of flavonoids including apigeninidin, a stable 3-deoxyanthocyanidin and potential fungal growth inhibitor, which accounts for 84% of the total extract. Non-clinical in vitro and in vivo studies support previous indications that this variety of Sorghum bicolor possesses several biologically active compounds with potent antioxidant, anti-inflammatory, anti-aging and neuro-protective properties.  Clinical studies show that SBLS has the ability to boost hemoglobin concentrations in anemic conditions and most remarkably to increase CD4 count in HIV-positive patients. The multiple effects and high safety profiles of this extract may encourage its development as a therapeutic agent for the treatment of anemia, chronic inflammatory conditions or in the symptomatic management of HIV infections. This review describes the potential therapeutic aspects of SBLS extract and its potential benefits.

scholarly journals The Pattern of Haematological Changes in the Baseline Blood Cell Counts and the CD4⁺ T Lymphocyte Levels among Antiretroviral Therapy Naïve Adult HIV Positive Patients in a Nigerian Hospital

2020 ◽  
Vol 10 (03) ◽  
pp. 77-88
Author(s):  
Taiwo Modupe Balogun ◽  
Abiola Omosalewa Alao ◽  
Olawunmi Femi Olaosebikan ◽  
Adewunmi James Aremu ◽  
Oladunni Olajumoke Adegbite
Keyword(s):  
Antiretroviral Therapy ◽  
Blood Cell ◽  
T Lymphocyte ◽  
Hiv Positive ◽  
Cell Counts ◽  
Blood Cell Counts ◽  
Haematological Changes

scholarly journals Antibiotic Resistance of Enteric Bacteria in HIV-Infected Patients at the Banka Ad-Lucem Hospital, West Region of Cameroon

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Ornella J. T. Ngalani ◽  
Armelle T. Mbaveng ◽  
Wiliane J. T. Marbou ◽  
Roland Y. Ngai ◽  
Victor Kuete
Keyword(s):  
Escherichia Coli ◽  
Klebsiella Pneumoniae ◽  
T Lymphocyte ◽  
Enterobacter Aerogenes ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Hs Crp ◽  
Enteric Disorders ◽  
Hiv Seropositive ◽  
Hiv Negative

Human immunodeficiency virus (HIV) infection is a serious problem throughout the world and especially in developing countries. This study was conducted to define the bacterial aetiologies of enteric disorders and their association with CD4+ T-lymphocyte cell count and serum hs-CRP in HIV-seropositive patients coming for consultation at the AD-Lucem Banka Hospital. Stool samples from one-hundred HIV-positive patients with enteric disorders and forty HIV negative patients with enteric disorders were examined for the presence of bacteria by different diagnostic techniques. CD4+ T-lymphocyte count and serum hs-CRP of HIV-positive and HIV-negative patients were examined, respectively, by flux cytometry and the ELISA solid-phase direct sandwich method. Among all the participants, 39 (26.35%) were males and 109 (73.65%) were females. HIV-seropositive mean age (43.79 years) was significantly higher compared to HIV-seronegative (27.13 years) patients (p<0.000). The average values of CD4+ T-cell count (p<0.0001), lymphocytes (p=0.0258), monocytes (p=0.0317), and total WBC count (p=0.0277) were significantly higher in HIV− patients compared to HIV+ patients. Salmonella sp., Escherichia coli, and Klebsiella pneumoniae were more isolated in HIV+ patients 5 (83.33), 18 (75.00), and 37 (71.15) compared to HIV− patients 1 (16.67), 6 (25.00), and 15 (28.85), respectively. Majority of isolates were susceptible to IPM, NOR, and CIP. Klebsiella pneumoniae, the most prevalent isolate, showed resistance to AMC (45.95) in HIV+ patients, whereas in HIV− patients, Enterobacter aerogenes and Shigella sp. showed resistance to AMC (80.00% and 85.71%, respectively) and to CFM (80.00% and 57.14%, respectively). Enterobacter aerogenes (40.00%) and Shigella sp. (14.29) isolates showed multidrug resistance in HIV− patients, whereas Escherichia coli (5.56%) and Klebsiella pneumoniae (2.70%) showed multidrug resistance in HIV+ patients. Understanding the burden of bacteria disease in HIV patients as shown in the present study is important for planning effective control programs for the overall reduction of bacteria diseases in HIV-infected patients.

Analysis of CCR5, CCR2, CX3CR1, and SDF1 Polymorphisms in HIV-Positive Treated Patients: Impact on Response to HAART and on Peripheral T Lymphocyte Counts

2006 ◽  
Vol 22 (2) ◽  
pp. 153-162 ◽  
Author(s):  
Bénédicte Puissant ◽  
Francis Roubinet ◽  
Patrice Massip ◽  
Karine Sandres-Saune ◽  
Pol-André Apoil ◽  
...  
Keyword(s):  
T Lymphocyte ◽  
Hiv Positive

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

2008 ◽  
Vol 26 (27) ◽  
pp. 4418-4425 ◽  
Author(s):  
Minal Barve ◽  
James Bender ◽  
Neil Senzer ◽  
Casey Cunningham ◽  
F. Anthony Greco ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Response ◽  
Small Cell Lung Cancer ◽  
Clinical Efficacy ◽  
T Lymphocyte ◽  
Cell Lung Cancer ◽  
Cytotoxic T Lymphocyte ◽  
Small Cell ◽  
Low Grade ◽  
Small Cell Lung

Purpose Generation of broad cytotoxic T-lymphocyte responses against multiple epitopes and tumor-associated antigens (TAAs) may provide effective immunotherapy in patients with cancer. We evaluated a single-vial peptide vaccine consisting of nine HLA-A2 supertype-binding epitopes (two native and seven analog epitopes modified for optimal HLA binding or T-cell receptor stimulation) covering five TAAs and the universal helper pan-DR epitope, formulated as a stable emulsion with incomplete Freund's adjuvant (Montanide ISA 51; Seppic SA, Paris, France). The clinical efficacy, safety, and multiepitope immunogenicity of IDM-2101 was evaluated in patients with stage IIIB or IV non–small-cell lung cancer (NSCLC). Patients and Methods A total of 63 patients were enrolled who were positive for HLA-A2. End points included survival, safety, and immune response. IDM-2101 (previously EP-2101) was administered every 3 weeks for the first 15 weeks, then every 2 months through year 1, then quarterly through year 2, for a total of 13 doses. Epitope-specific cytotoxic and helper T-lymphocyte immunogenic responses were measured by the interferon gamma enzyme-linked immunosorbent spot assay. Results No significant adverse events were noted. Low-grade erythema and pain at the injection site were the most common adverse effects. One-year survival in the treated patients was 60%, and median survival was 17.3 months. One complete and one partial response were identified. Survival was longer in patients demonstrating an immune response to epitope peptides (P < .001). Conclusion IDM-2101 was well tolerated, and evidence of efficacy was suggested.

scholarly journals Assessing crop model improvements through comparison of sorghum ( sorghum bicolor L. moench) simulation models: A case study of West African varieties

2017 ◽  
Vol 201 ◽  
pp. 19-31 ◽  
Author(s):  
F.M Akinseye ◽  
M. Adam ◽  
S.O Agele ◽  
M.P. Hoffmann ◽  
P.C.S Traore ◽  
...  
Keyword(s):  
Sorghum Bicolor ◽  
Simulation Models ◽  
Crop Model ◽  
West African ◽  
Sorghum Bicolor L
Sign in / Sign up

Export Citation Format

Share Document